The Food and Drug Administration is investigating whether convalescent plasma from recovered COVID-19 patients contains viable antibodies to treat SARS-CoV-2 in the sickest patients. While FDA trials continue, providers may request the plasma for investigational use in patients with the most serious and life-threatening COVID-19 infections. For more information, visit FDA.gov.

Related News Articles

Headline
The Federal Emergency Management Agency and Department of Health and Human Services have created a Supply Chain Stabilization Task Force to address the need…
Headline
The AHA today released a Special Bulletin with information and FAQs on the Federal Reserve emergency lending program included in the Coronavirus Aid, Relief…
Headline
Vice President Pence, on behalf of President Trump and the White House Coronavirus Task Force, Sunday sent a letter to the nation's hospitals requesting that…
Headline
The Centers for Medicare & Medicaid Services yesterday released a substantial number of new waivers related to COVID-19. The waivers apply nationwide and…
Headline
The AHA today asked the Department of Health and Human Services and Centers for Medicare & Medicaid Services to directly and expediently distribute to…
Headline
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations including the AHA, applauded Congress’ important step to …